Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Chongqing Hongyuantang Medicine Co. Ltd. currently maintains 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner, creating a focused prosecution environment for the company's active filing. The portfolio's activity is also restricted to 1 distinct art unit, which suggests a specific technical focus within the broader biotechnology sector.
The busiest examiner for this entity is REDWOOD, CHRISTOPHER EVAN, who is responsible for 1 busiest examiner pending office action. Because REDWOOD, CHRISTOPHER EVAN oversees the only active matter in the portfolio, the prosecution effort is entirely centralized. This allows the legal team to develop a strategy based on the specific feedback and prior art interpretations provided by this examiner during the review process.
For a practitioner, the presence of 1 distinct examiner and 1 distinct art unit in the Biotechnology & Pharmaceuticals sector means that the 1 pending office action can be managed without the complexity of varying examiner standards. The focus remains on the technical arguments required for this single case. This streamlined arrangement facilitates a clear and direct path toward resolving the outstanding office action with the assigned examiner.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| REDWOOD, CHRISTOPHER EVAN | 1 | 0.0% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18230686 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | REDWOOD, CHRISTOPHER EVAN | 79d overdue |
| Art Unit | Apps |
|---|---|
| 1629 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18230686 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | REDWOOD, CHRISTOPHER EVAN | 1629 | §103 | Final Rejection | 79d overdue | Pending | Aug 07, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial